GT Biopharma (GTBP) Notes Payables (2013 - 2024)

GT Biopharma (GTBP) has reported Notes Payables for 9 consecutive years, with $394000.0 the latest figure, recorded in Q1 2024.

• On a quarterly basis, Notes Payables fell 86.53% year-over-year to $394000.0 in Q1 2024; TTM through Mar 2024 was $394000.0, a 86.53% decrease from a year earlier, with the FY2023 full-year figure at $1.1 million, up 5436.84% from the prior year.
• Notes Payables was $394000.0 for Q1 2024 at GT Biopharma, down from $1.1 million in the prior quarter.
• Over five years, Notes Payables peaked at $2.9 million in Q1 2023 and troughed at $19000.0 in Q4 2022.
• A 5-year average of $667142.9 and a median of $373000.0 in 2020 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables soared 5436.84% in 2023 and slumped 86.53% in 2024, its largest moves.
• Over 5 years, Notes Payables stood at $384000.0 in 2020, then tumbled by 64.06% to $138000.0 in 2021, then sank by 86.23% to $19000.0 in 2022, then soared by 5436.84% to $1.1 million in 2023, then plunged by 62.55% to $394000.0 in 2024.
• The last three Notes Payables figures came in at $394000.0 (Q1 2024), $1.1 million (Q4 2023), and $1.1 million (Q3 2023), per Business Quant data.